SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Amortization of Debt Issuance Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Amortization of Debt Issuance Costs of $50.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2025-08-13
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2025-06-30 was $50.00K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2025-03-31 was $50.00K, a 95.36% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2024-06-30 was -$386.50K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2024-03-31 was $1.08M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for fiscal 2023 was $1.52M, a 359.00% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt issuance costs for fiscal 2022 was $331.98K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-06-30 | $50.00K 10-Q · filed 2025-08-13 | $100.00K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $50.00K 10-Q · filed 2025-05-08 | |||
| 2024-06-30 | -$386.50K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $691.75K 10-Q · filed 2024-09-04 | $223.43K derived: sum of 3 quarters · filed 2024-09-04 | -$314.87K derived: sum of 4 quarters · filed 2024-09-04 |
| 2024-03-31 | $1.08M 10-Q/A · filed 2024-09-04 | $609.93K derived: sum of 2 quarters · filed 2024-09-04 | $71.63K derived: sum of 3 quarters · filed 2024-09-04 | |
| 2023-12-31 | -$468.32K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | -$1.01M derived: sum of 2 quarters · filed 2024-09-04 | $1.52M 10-K/A · filed 2024-09-04 | |
| 2023-09-30 | -$538.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.99M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $2.53M 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $331.98K 10-K/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |